Kura Oncology shares tumbled 40% in premarket trading

Kura Oncology shares tumbled 40% in premarket trading.The FDA has slapped a clinical hold on the early-stage program for one of Kura’s cancer drugs following a patient’s death in a clinical trial.

The biotech $KURA reported early Wednesday that the Phase Ib study of KO-539 for acute myeloid leukemia would be halted, suspending enrollment, while researchers and the FDA probed the death. Patients already on the drug can continue taking it.